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A report of the Cold Spring Harbor Laboratory meeting
‘Mechanisms and Models of Cancer’, Cold Spring Harbor,
USA, 13-17 August 2008.
The Mechanisms and Models of Cancer meeting held at the
Cold Spring Harbor Laboratory this year brought together
researchers from all over the world to discuss new advances
in the field. Several distinct themes emerged: the use of
genetic screens designed to integrate mouse and human
cancer data; new insights into the mechanisms of well-
studied oncogenes and tumor suppressors; and advances in
the area of experimental therapeutics. This report presents a
few of the highlights.
G Ge en ne et ti ic c   s sc cr re ee en ns s   t to o   i id de en nt ti if fy y   n no ov ve el l   o on nc co og ge en ne es s   a an nd d
t tu um mo or r   s su up pp pr re es ss so or rs s
Lynda Chin (Dana-Farber Cancer Institute, Boston, USA)
described a strategy for using cross-species comparisons of
mouse-human genomic data to search for melanoma tumor
suppressors and metastasis mediators. First, gene-
expression profiling was used to compare two mouse models
of melanoma that differ in their metastatic potential. The list
of differentially expressed genes was then used to interro-
gate human genomic data from primary and metastatic
melanomas. Using the human data as a filter, Chin and her
colleagues identified a metastatic melanoma signature of
360 genes. Testing these genes in an in vitro functional
assay of invasion narrowed the list down to 20, most of which
had not been implicated in metastasis previously. These 20
genes were shown to be correlated with progression in a
variety of human tumor types, and the expression patterns
of 12 genes showed high correlation with breast cancer
progression as well as being predictive of survival. Lawrence
Kwong (Dana-Faber Cancer Institute, Boston, USA) from
Chin’s group described a related study on the use of
comparative genomic hybridization (CGH) data from
primary and metastatic melanoma samples to identify
chromosomal regions lost in metastatic disease. RNA
interference with pooled small hairpin RNAs (shRNAs) was
then used to target the genes in these regions and test their
ability to decrease tumor latency in an in vivo mouse
melanoma model. Seven candidate genes were identified
and are currently being tested to determine whether they are
indeed novel tumor suppressors for melanoma or other
tumors. These studies very nicely illustrated the power of
cross-species comparisons for novel gene discovery.
Genetic screens can also be designed to investigate
particular gene families. Michael Hemann (Massachusetts
Institute of Technology, Cambridge, USA) presented work
from his lab using a pooled shRNA screen in vivo to deter-
mine the importance of BCL2 family members in responses
to chemotherapy. Using a transplantable B-cell lymphoma
mouse model, they compared pre- and post-chemotherapy
levels of different shRNAs in a pooled screen to identify
genes involved in chemotherapy resistance. Bid, a gene
whose protein product participates in the extrinsic death
pathway, was identified as a critical mediator of chemo-
therapy resistance in vivo. This effect was not seen in vitro,
underscoring the importance of in vivo studies. Karen
Cichowski (Harvard Medical School, Boston, USA) pre-
sented an in vitro shRNA screen investigating whether
members of the Ras-GAP family other than the negative Ras
regulator NF1 show tumor-suppressive functions. The family
member DAB2IP was identified as a novel tumor sup-
pressor, and in an orthotopic (transformed human cells
introduced into the mouse prostate) transplant mouse
model for prostate cancer, knockdown of DAB2IP expression
was more potent in inducing tumors than was expression of
the H-Ras oncogene. Loss of DAB2IP also resulted in tumor
metastasis in this model. This effect could be attributed to
the fact that DAB2IP is a much more potent inducer of the
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Several talks described novel roles for a variety of oncogenes
and tumor suppressors. Gigi Lozano (University of Texas
MD Anderson Cancer Center, Houston, USA) presented
work using a mouse model to study the function of the
mutant tumor suppressor protein p53175H, which carries a
mutation frequently found in human cancer. In p53175H
mutant mice, which have a gain-of-function phenotype
characterized by increased metastasis that is not seen in p53
null mice, p53 was unstable in normal tissues, and only
some, but not all, tumors showed p53 stability. To under-
stand the molecular basis of this lack of stability, the mutant
mice were crossed with either Mdm2-/- or p16INK4A-null
mice. In both cases, p53 was stabilized in the progeny. This
confirmed that the point mutant p53 is regulated by mdm2
in a similar fashion to wild-type p53. These results demon-
strate that p53 stabilization is not synonymous with muta-
tion. Lozano pointed out that this has important clinical
implications, as it suggests that loss of the mdm2-p53
interaction may actually help to stabilize the mutant form of
p53 and make tumors more aggressive. Importantly in this
regard, mdm2-null, p53172H mice have increased
metastasis and decreased survival compared to p53172H
mdm2 wild-type mice.
Gerard Evan (University of California, San Francisco, USA)
presented work from his laboratory showing that there is a
threshold of expression that tips the balance between the
tumor suppressor and oncogene activities of Myc. In a
transgenic mouse model in which ubiquitous Myc
expression can be induced by tamoxifen, the phenotype
varied depending on the level of expression; mice
homozygous for the Myc transgene showed massive cell
proliferation in most organs on Myc induction, whereas the
heterozygous mice did not. Using a different transgenic
mouse in which even higher levels of Myc expression in the
pancreas can be achieved, Myc activation resulted in
widespread apoptosis in this organ. Evan also presented
results suggesting that the level of expression of specific
Myc targets may be the explanation for the different
outcomes.
The protein kinase Aurora A is frequently found amplified
or overexpressed in human cancers, and TerryVan Dyke
(National Cancer Institute, Bethesda, USA) presented work
from her laboratory aimed at elucidating the roles of the
Aurora A family. Using a variety of mouse models with
different levels of Aurora A expression, they found that a
threshold level of Aurora A is required for the mice to be
viable. Upon deletion of Aurora A in serum-starved mouse
embryonic fibroblasts, the cells enter, but cannot complete,
mitosis. Roughly 30% of these cells had monopolar
spindles with an activated spindle-checkpoint response.
When Aurora-A-null embryos that did not survive beyond
blastocyst stage were examined, monopolar spindles were
also present, confirming the in vitro studies.
As solid tumors develop, they are subject to decreased
oxygen availability (hypoxia). Celeste Simon (University of
Pennsylvania School of Medicine, Philadelphia, USA)
discussed her laboratory’s efforts to understand the cellular
response to reduced oxygen availability. This response is
largely regulated at the transcriptional level by the hypoxia-
inducible factors HIF-1α and HIF-2α. These two trans-
cription factors have distinct effects on cellular self-renewal
pathways: HIF-1α expression decreases cell proliferation
whereas HIF-2α has the opposite effect; HIF-1α can form a
complex with Notch whereas HIF-2α regulates Oct4.
Simon’s results suggest that these differences are at least
partially due to opposing effects of the two HIFs on c-Myc:
HIF-1α inhibits c-Myc activity whereas HIF-2α promotes it.
She also reported that a hypoxic environment leads to
increased Wnt/β-catenin signaling in several stem-cell
populations, and that these hypoxia-inducible effects are
attenuated upon differentiation.
To determine the relevance of the distinct roles of HIF-1α
and HIF-2α in oncogenesis, Simon’s group has focused on
renal cell carcinoma (RCC). She reported that 30% of RCCs
express HIF-2α but not HIF-1α, and that these tumors seem
to have increased activation of c-Myc targets that correlates
with increased cell proliferation. Furthermore, HIF-2α-
positive RCCs also have increased expression of DNA
damage response genes, and there is evidence of a decrease
in genomic instability. Thus, RCCs can be separated into
biologically distinct categories on the basis of VHL (Von
Hippel Lindau) status and HIF-1α expression. Simon’s
results provide a beautiful example of how mouse models, in
vitro  mechanistic studies and analysis of human tumor
specimens can be combined to garner new insight into the
distinct mechanisms that drive tumorigenesis in histo-
logically similar tumors.
Alicia Cole (Beatson Institute for Cancer Research, Glasgow,
UK) presented an analysis in conditional-mutant APC mice,
aimed at determining why loss of the tumor suppressor APC
primarily affects the intestine and not other tissues in which
it is deleted. Even though these mice showed high levels of
loss of APC in the kidneys, only a small proportion developed
renal cancers. Cole described how, unlike the situation in the
intestine,  APC loss in the kidney apparently induces cell
senescence. When these mice were crossed with either p21-
null or INK4a-null mice, renal cancers developed more
frequently in the progeny because of the loss of the
senescence response to APC loss. Johannes Zuber (Cold
Spring Harbor Laboratory, New York, USA) presented work
investigating the different responses to chemotherapy in
acute myelogenous leukemias (AMLs) bearing different
translocations. Using a mosaic mouse model of leukemia in
which the mice expressed either the AML-ETO or MLL-ENL
fusions, he and his colleagues found increased survival in the
AML-ETO mice after treatment with cyclophosphamide, but
no benefit of the same drug in MLL-ENL-induced leukemias.
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resulted in an increase in the tumor suppressor proteins p53
and p21 in the AML-ETO mice, but not in the MLL-ENL
mice.
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Several groups presented work aimed at increasing the
clinical benefit of therapeutic treatments through new
insights into how cells respond to such treatments. Seiko
Ishida (University of California, San Francisco, USA)
described how copper chelators synergize with the chemo-
therapeutic agent cisplatin in a mouse model of cervical
cancer. Cells respond to the copper-chelating agent by
increasing the levels of a copper transporter (to make up for
the copper deficiency), which in turn allows the cells to take
up more cisplatin. The double treatment enhanced the
number of cisplatin adducts specifically in the tumors. This
work suggests that copper chelators may enhance cisplatin’s
efficacy without an increase in its toxicity.
Precisely targeted cancer therapies are generally desirable, but
some have not proved effective when tested clinically. As one
example, inhibition of individual receptor tyrosine kinases is
of limited benefit in glioblastoma. Jayne Stommel (Harvard
Medical School, Boston, USA) presented work demonstrating
that combinations of inhibitors may be more effective. She
showed that one possible reason for the lack of benefit of
inhibiting the epidermal growth factor receptor (EGFR) in
glioblastoma is because other receptor tyrosine kinases are
activated and can compensate. Other primary human cancers
also showed multiple activated receptor kinases. Targeting of
multiple receptor tyrosine kinases in the glioblastoma cells
reduced cell viability and inhibited proliferation.
The inhibition of the BCR-Abl oncoprotein, for example by
the drug imatinib (Gleevec), is beneficial in chronic myelo-
genous leukemia (CML) but less so in acute lymphocytic
leukemia (ALL). Richard Williams (St Jude Children’s
Research Hospital, Memphis, USA) showed that the
duration of BCR-Abl inhibition in a transplantable mouse
model of ALL was dependent on the tumor burden as well as
the intensity of treatment. On continuous treatment, most of
the leukemic mice spontaneously relapsed, developing B-cell
leukemia with point mutations in the kinase domain of BCR-
Abl that are known to confer drug resistance. With shorter-
duration treatment, however, relapse was primarily seen in
the central nervous system, with a low level of the mutation
known to confer the greatest drug resistance. James
DeGregori (University of Colorado Denver School of
Medicine, Aurora, USA) described a shRNA-based screen in
CML and ALL cell lines to uncover synthetic lethal
interactions in the context of imatinib treatment.
Surprisingly, multiple members of the noncanonical
Wnt/calcium pathway were implicated in sensitivity to
imatinib. Knockdown of members of this pathway in either
CML or ALL led to increased sensitivity to BCR-Abl
inhibition.
Galina Selivanova (Karolinska Institute, Stockholm, Sweden)
discussed a novel small-molecule inhibitor of p53 called
RITA. In contrast to the inhibitor Nutlin, which binds directly
to Mdm2, inhibiting its interaction with and the subsequent
degradation of, p53, RITA directly binds p53, preventing its
interaction with Mdm2. RITA was able to induce p53-
dependent apoptosis in cell lines and suppress tumor
formation. This is in contrast to the effects of Nutlin, which
mainly induces a p21-dependent cell-cycle arrest. Interes-
tingly, the authors found that RITA treatment actually results
in less p21, both through a novel direct Mdm2-mediated
degradation and through Mdm2 degradation of a p53
cofactor known to be important for expression of p21 mRNA.
Participants at the 2008 Mechanisms and Models of Cancer
meeting enjoyed hearing about much new and unpublished
work and taking part in lively and informative discussion,
and we look forward to the 2009 meeting, which will be held
in San Diego.
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